PMID- 22198800
OWN - NLM
STAT- MEDLINE
DCOM- 20131104
LR  - 20211021
IS  - 1437-7772 (Electronic)
IS  - 1341-9625 (Linking)
VI  - 18
IP  - 2
DP  - 2013 Apr
TI  - Health-related quality of life in Japanese patients with metastatic renal cell 
      carcinoma treated with sunitinib.
PG  - 220-5
LID - 10.1007/s10147-011-0364-6 [doi]
AB  - BACKGROUND: To analyze the impact of sunitinib treatment on health-related 
      quality of life (HRQOL) in Japanese patients with metastatic renal cell carcinoma 
      (mRCC). METHODS: This study prospectively included 90 consecutive patients with 
      mRCC treated with sunitinib for at least 3 months. HRQOL in these patients was 
      assessed using the Medical Outcomes Study 36-Item Short Form (SF-36) consisting 
      of 8 multi-item scales measuring health status. RESULTS: There were no 
      significant differences in any of the 8 scores in these 90 patients between 
      surveys conducted before and 3 months after sunitinib treatment. Three months 
      after treatment, all 8 scores in patients who had some degree of tumor shrinkage 
      were more favorable than those in the remaining patients, and there were 
      significant differences in 2 of the 8 scale scores (role limitations because of 
      emotional problems, mental health) between these two groups. However, there were 
      no significant differences in any scale scores except one (social function) 
      between patients with and without severe adverse events (AEs). Furthermore, a 
      significant time-dependent improvement was observed in one score (body pain), 
      while there were no significant differences in the remaining 7 scores 3, 6 and 
      12 months after sunitinib treatment in 29 patients who could be followed for at 
      least 12 months. CONCLUSIONS: Although this was a non-randomized study including 
      a comparatively small number of patients, these findings suggest that efficacy 
      rather than AE is likely to be associated with HRQOL in Japanese mRCC patients 
      treated with sunitinib.
FAU - Miyake, Hideaki
AU  - Miyake H
AD  - Division of Urology, Kobe University Graduate School of Medicine, 7-5-1 
      Kusunoki-cho, Chuo-ku, Kobe, 650-0017, Japan. hideakimiyake@hotmail.com
FAU - Harada, Ken-Ichi
AU  - Harada K
FAU - Kusuda, Yuji
AU  - Kusuda Y
FAU - Fujisawa, Masato
AU  - Fujisawa M
LA  - eng
PT  - Journal Article
DEP - 20111227
PL  - Japan
TA  - Int J Clin Oncol
JT  - International journal of clinical oncology
JID - 9616295
RN  - 0 (Indoles)
RN  - 0 (Pyrroles)
RN  - V99T50803M (Sunitinib)
SB  - IM
MH  - Aged
MH  - Carcinoma, Renal Cell/*drug therapy/epidemiology/pathology
MH  - Female
MH  - Health Status
MH  - Humans
MH  - Indoles/*administration & dosage
MH  - Japan
MH  - Kidney Neoplasms/*drug therapy/epidemiology/pathology
MH  - Lymph Nodes/drug effects/pathology
MH  - Lymphatic Metastasis/pathology
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Staging
MH  - Prospective Studies
MH  - Pyrroles/*administration & dosage
MH  - *Quality of Life
MH  - Sunitinib
MH  - Surveys and Questionnaires
MH  - Treatment Outcome
EDAT- 2011/12/27 06:00
MHDA- 2013/11/05 06:00
CRDT- 2011/12/27 06:00
PHST- 2011/10/17 00:00 [received]
PHST- 2011/12/08 00:00 [accepted]
PHST- 2011/12/27 06:00 [entrez]
PHST- 2011/12/27 06:00 [pubmed]
PHST- 2013/11/05 06:00 [medline]
AID - 10.1007/s10147-011-0364-6 [doi]
PST - ppublish
SO  - Int J Clin Oncol. 2013 Apr;18(2):220-5. doi: 10.1007/s10147-011-0364-6. Epub 2011 
      Dec 27.